Supplementary materials: Network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema

<p dir="ltr"><b>These are peer-reviewed supplementary materials for the article </b><b>'</b><b>Network meta-analysis for indirect </b><b>comparison of lanadelumab and </b><b>berotralstat for the treatment of </b><b>hereditary angioedema</b><b>' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b></p><p dir="ltr"><b><u>Supplementary data</u></b></p><ul><li><b>Supplementary Table 1: </b>Inclusion and exclusion criteria for the 2018 SLR.</li><li><b>Supplementary Table 2: T</b>rial design of the studies in the evidence network.</li></ul><p dir="ltr"><b><u>Supplementary methods</u></b></p><ul><li><b>Statistical details on methodology</b></li></ul><p dir="ltr"><b>Aim:</b> With no head-to-head studies comparing the effectiveness of lanadelumab and berotralstat for prevention of hereditary angioedema (HAE) attacks, this networkmeta-analysis (NMA) aimed to indirectly compare the effectiveness of these treatments. <b>Materials & methods:</b> The NMA, using the published data from Phase III trials, was performed using a frequentist weighted regression-based approach following Rucker et al. Efficacy outcomes of interest were HAE attack rate per 28 days and ≥90% reduction in monthly HAE attacks. <b>Results & conclusion:</b> In this NMA, lanadelumab 300 mg administered every 2 weeks or every 4 weeks was associated with statistically significantly higher effectiveness versus berotralstat 150 mg once daily (q.d.) or 110 mg q.d. for both efficacy outcomes assessed.</p>